Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. by Hu, Q et al.
T
h
e 
Jo
u
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2004/04/1065/11 $8.00
Volume 199, Number 8, April 19, 2004 1065–1075
http://www.jem.org/cgi/doi/10.1084/jem.20022212
 
1065
 
Blockade of Attachment and Fusion Receptors Inhibits 
HIV-1 Infection of Human Cervical Tissue
 
Qinxue Hu,
 
1
 
 Ines Frank,
 
2
 
 Vennansha Williams,
 
2
 
 John J. Santos,
 
2
 
 Patricia Watts,
 
1
 
 
 
George E. Griffin,
 
1
 
 John P. Moore,
 
3
 
 Melissa Pope,
 
2
 
 and Robin J. Shattock
 
1
 
1
 
Department of Cellular and Molecular Medicine, Infectious Diseases, St. George’s Hospital Medical School, 
London SW17 ORE, UK
 
2
 
Center for Biomedical Research, Population Council, New York, NY 10021
 
3
 
Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021
 
Abstract
 
Identification of cellular factors involved in HIV-1 entry and transmission at mucosal surfaces is
critical for understanding viral pathogenesis and development of effective prevention strategies.
Here we describe the evaluation of HIV-1 entry inhibitors for their ability to prevent infection
of, and dissemination from, human cervical tissue ex vivo. Blockade of CD4 alone or CCR5
and CXCR4 together inhibited localized mucosal infection. However, simultaneous blockade
of CD4 and mannose-binding C-type lectin receptors including dendritic cell–specific intercellular
adhesion molecule–grabbing integrin was required to inhibit HIV-1 uptake and dissemination
by migratory cells. In contrast, direct targeting of HIV-1 by neutralizing mAb b12 and CD4-
IgG2 (PRO-542) blocked both localized infection and viral dissemination pathways. Flow
cytometric analysis and immunostaining of migratory cells revealed two major populations,
CD3
 

 
HLA-DR
 

 
 and CD3
 

 
HLA-DR
 

 
 cells, with a significant proportion of the latter also
expressing dendritic cell–specific intercellular adhesion molecule–grabbing integrin. Bead depletion
studies demonstrated that such HLA-DR
 

 
 cells accounted for as much as 90% of HIV-1 dissem-
ination. Additional studies using immature monocyte-derived dendritic cells demonstrated that
although mannose-binding C-type lectin receptors and CD4 are the principal receptors for
gp120, other mechanisms may account for virus capture. Our identification of the predominant
receptors involved in HIV-1 infection and dissemination within human cervical tissue high-
light important targets for microbicide development.
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Introduction
 
The majority of HIV-1 infections are acquired by mucosal
exposure, with heterosexual transmission as the leading
mode of HIV-1 infection worldwide. The HIV-1 epidemic
is increasingly affecting women, particularly in Sub-Saharan
Africa where they represent over 55% of those infected
(http://www.unaids.org). In the absence of a protective
vaccine, such women are particularly vulnerable to HIV-1
infection as they often cannot control sexual encounters
and/or condom use. Thus, there is an urgent need to develop
female-controlled prevention methods, which could be
used without partner consent. Although the potential role
of microbicides, compounds that could be applied topically
to prevent HIV-1 transmission, is clearly recognized, their
efficacy may be critically dependent on effective blockade
of all potential receptors involved in HIV-1 entry and dissem-
ination within genital mucosa (1).
The lower female genital tract is lined by stratified squa-
mous epithelial cells (vagina and ectocervix) or a single
epithelia monolayer (endocervix). It is unclear how HIV-1
particles or cell-associated virus penetrate intact mucosa
and initiate infection. Although several mechanisms for
HIV-1 transmission across genital epithelium have been
proposed, their in vivo relevance remains controversial (2).
We have demonstrated previously that intact normal cervical
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 Env, envelope glycoprotein; DC-SIGN,
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MCLR, mannose-binding C-type lectin receptor; MDDC, monocyte-
derived DC; MR, mannose receptor.
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and vaginal epithelium provides a significant barrier to
HIV-1 infection (3), suggesting mucosal infection may re-
quire some perturbation of epithelial integrity. Although ex
vivo studies using human cervical explant tissue have iden-
tified subepithelial CD4 T cells and macrophages as the ini-
tial target for HIV-1 infection (3, 4), the principal recep-
tors involved have not been defined. HIV-1 isolates from
newly infected individuals predominantly use CCR5 (R5),
suggesting that they are either selectively transmitted and/
or preferentially amplified, whereas CXCR4 using (X4)
isolates can become more common later in the disease
course (5). We have observed previously preferential repli-
cation of the R5 virus HIV-1
 
BaL
 
 in cervical tissues. How-
ever, R5, X4, and dual-tropic R5X4 HIV-1 isolates can all
infect PHA-activated cervical tissues (3), suggesting that
immune activation may increase susceptibility to additional
HIV-1 phenotypes. Cervical and vaginal coreceptor ex-
pression levels are relatively low compared with other tis-
sues (6), perhaps due, at least in part, to high levels of en-
dogenous SDF-1 and 
 

 
-chemokine expression by stratified
epithelium (7). This suggests that coreceptor expression
may be a rate-limiting step governing HIV-1 infection.
Studies using macaque models of vaginal transmission
have suggested a critical role for DCs in mucosal SIV infec-
tion and rapid dissemination to draining lymph nodes (2).
Observations that in vitro–derived human DCs can bind
HIV-1 without becoming infected and maintain or even
enhance HIV-1 infection of T cells have led to the sugges-
tion that these cells may be critical in mucosal transmission
of HIV-1 (8–11). The ability of mature DCs to capture
HIV-1 in the absence of infection has been linked to the
mannose-binding C-type lectin receptor (MCLR) DC-
specific intercellular adhesion molecule–grabbing integrin
(DC-SIGN) (or CD209) (9). DC-SIGN binds HIV-1 by
interaction with high mannose residues expressed on viral
gp120 and can enhance infection both in trans and cis (8,
11). The expression of DC-SIGN on subepithelial cervical
and vaginal DCs (9, 12) suggests it may have a pivotal role
in HIV-1 transmission, either promoting localized mucosal
infection, where coreceptor levels may be limiting and/or
facilitating dissemination of HIV-1 through migration of
DC-SIGN–positive DCs to secondary lymphoid organs.
However, recent evidence suggests that other MCLRs like
mannose receptor (MR) (13) and non-MCLRs (14) may
also contribute to virus capture and dissemination. Al-
though these potential pathways have been the source of
much conjecture, to date they have not been tested using
human mucosal tissue.
 
Materials and Methods
 
Viruses, Cell Lines, Inhibitors, and Antibodies.
 
HIV-1 BaL and
NL4–3 (obtained from Centralized Facility for AIDS Reagents)
were grown in PM1 cells. Low-passage strains (SL2, 2044, and
2076; donated by P. Clapham, University College London, Lon-
don, UK) were grown in PHA-stimulated PBMCs supplemented
with 20 U/ml of recombinant human IL-2. The AT-2–inacti-
vated R5 isolate HIV-1
 
ADA
 
 was provided by J.D. Lifson (AIDS
Vaccine Program, National Cancer Institute [NCI], Frederick,
MD). DC-SIGN–expressing THP1 cell line was provided by
V.N. KewalRamani (HIV Drug Resistance Program, NCI, Fred-
erick, MD). HIV-1 inhibitors used included mAbs: anti-CD4
(clone RPA-T4; BD Biosciences), anti-MR (clone19.2; BD Bio-
sciences), anti–galactosyl ceramide (GalCer) (mAb342; Chemi-
con International), anti–DC-SIGN (a 1:1 mixture of clone507
and clone526; provided by R.W. Doms, University of Pennsyl-
vania, PA), mAb b12 (provided by D.R. Burton, The Scripps
Research Institute, La Jolla, CA), unconjugated and biotinylated
CD4-IgG2 (bCD4-IgG2) (provided by W.C. Olson, Progenics
Pharmaceuticals, Tarrytown, NY), and chemokine antagonists
AOP-RANTES (Serono Pharmaceutical Research Institute),
TAK-779 (TAKeda Chemical Industries Ltd.), and AMD3100
(AnorMED). Human IgG and mouse IgG were purchased from
Serotec. Mannan was purchased from Sigma-Aldrich. Mouse
anti–human mAbs used for flow cytometry and immunostaining
include: CD11b-PE (Exalpha Biological); CD1a-FITC, CD3-
FITC, CD4-FITC, CD83-FITC, DC-SIGN-FITC, HLA-DR-
FITC, CD3-PE, CD4-PE, CD8-PE, CD14-PE, CD20-PE,
CD25-PE, CD80-PE, CD83-PE, and CD86-PE (BD Bio-
sciences); CD3-FITC, HLA-DR-ECD (PE-Texas red), CD19-
PE, CD56-PE, and CD83-PE (Beckman Coulter); and DC-
SIGN (DC4, DC28; provided by Robert W. Doms, University
of Pennsylvania, PA). Corresponding isotype-matched controls
were included in all stainings.
 
Infection of Human Cervical Tissues.
 
Cervical tissue was obtained
from women undergoing planned therapeutic hysterectomy in
the absence of any cervical pathology at St. George’s Hospital
(written consent was obtained from all tissue donors, according to
the Local Research Ethics Committee). 3-mm 
 

 
 3-mm explants
were cultured in 200 
 

 
l of supplemented RPMI 1640 as de-
scribed previously with modifications (3). Explants were preincu-
bated in the presence or absence of inhibitors for 1 h at 37
 

 
C be-
fore exposure to HIV-1. After a 2-h exposure at 37
 

 
C to virus
(5 
 
 
 
10
 
3
 
–5 
 
 
 
10
 
5
 
 TCID
 
50
 
), cervical explants were extensively
washed to remove unbound virus and inhibitor, and cultured for
14 d at 37
 

 
C in fresh plates, with each experimental condition
performed in triplicates. For migratory cell experiments, after ex-
posure to HIV-1, explants were cultured in the presence or ab-
sence of 100 ng/ml recombinant human MIP-3
 

 
 (R&D Sys-
tems; chemotactic for DCs) for 24–48 h at 37
 

 
C; migratory cells
that had emigrated out of the explants were then collected and
explants cultured for 14 d as above. Migratory cells (e.g., DCs;
pooled from three explants per condition) were washed and co-
cultured with indicator T cells (PM1 cells, 0.5 
 

 
 10
 
5
 
 cells/well in
96-well plate) at 37
 

 
C. In some cases, migratory cells were col-
lected and separated using CD3 or HLA-DR MicroBeads (Mil-
tenyi Biotec) according to the manufacturer’s protocol. Negative
and positive populations were cocultured with PM1 cells, respec-
tively, for 7 d. For experiments using activated tissue, explants
were cultured for 3 d before infection in the presence of PHA
(5 
 

 
g/ml). Stimulated explants were exposed to virus and washed
as above before culture in the presence of 20 U/ml IL-2. In
all cases, supernatants were collected every 3–4 d and stored
at 
 

 
80
 

 
C before subsequent measurement of p24 antigen by
ELISA.
 
Characterization of Migratory Cells by Flow Cytometry and Immuno-
fluorescent Microscopy.
 
Migratory cells were harvested from cer-
vical explants after culture in complete RPMI 1640 in the pres-
ence or absence of 100 ng/ml MIP-3
 

 
 for 12–48 h at 37
 

 
C. A
Cell Dissociation Sieve-Tissue Grinder kit (Sigma-Aldrich) was
used to remove tissue debris and big epithelial cells. Cells were
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monitored by three-color flow cytometry using CD3-PE and
HLA-DR-ECD mAbs combined with CD4-FITC or DC-
SIGN–FITC mAb. After staining, whole blood erythrocyte Lys-
ing kit (R&D Systems) was used to lyse remaining blood cells.
Cells were analyzed on FACStar (Becton Dickinson), and ac-
quired data were analyzed using WinMDI 2.8 software.
In some cases, migratory cells from cervical tissue were adhered
to alcian blue–pretreated microscope slides as previously described
(15). To identify DC subsets and T cells, adherent cells were im-
munostained with the following mAbs: anti–HLA-DR (clone
9.3C9, HB180; hybridoma supernatant; provided by Ralph Stein-
man, The Rockefeller University, New York, NY), anti–DC-
SIGN (5 
 

 
g/ml; clone 507), anti-MR (5 
 

 
g/ml; clone 19.2),
anti-CD3 (5 
 

 
g/ml; clone Leu-4; BD Bioscience), anti-CD83 (1:
50; clone PN IM2218; Beckman Coulter) including isotype con-
trols. To reduce nonspecific signals, cells were incubated with
blocking reagent provided with the TSA™ Kit (NEN Life Sci-
ence) supplemented with 0.05% saponin for permeabilization.
Saponin-containing blocking buffer was also used to dilute Ab. Be-
tween incubation steps, cells were washed with PBS. All steps
were performed at room temperature. After blocking, Ab includ-
ing isotype controls were added for 30 min, followed by a 30-min
incubation with a goat anti–mouse (GAM) Alexa Fluor594 IgG
(10 
 

 
g/ml; Molecular Probes) before cell nuclei were stained with
DAPI (1.75 ng/ml D-1306; Molecular Probes). Mounted slides
were examined by fluorescence microscopy.
 
Preparation and Culture of MDDCs and CD4
 

 
 T Cells.
 
Human
monocyte-derived DCs (MDDCs) were generated from a highly
enriched population of CD14
 

 
 monocytes. Briefly, PBMCs were
isolated from buffy coats obtained from the National Blood
Transfusion Service at London or the New York City Blood
Bank using a Ficoll-Hypaque density gradient followed by nega-
tive selection using the AutoMACS (Miltenyi Biotec) and the
Monocyte Isolation kit according to the manufacturer’s protocol,
or positive selection for CD14
 

 
 cells using the Magnetic Cell
Sorting System. The purity of the isolated CD14
 

 
 cells was
 

 
95% as assessed by flow cytometry. Immature MDDCs (iMD-
DCs) were cultured from monocytes in the presence of IL-4 (500
U/ml; R&D Systems) and GM-CSF (800 U/ml; R&D Systems),
respectively. At day 7, the phenotype of the cultured iMDDCs
was confirmed by flow cytometric analysis. The iMDDCs ex-
pressed high levels of DC-SIGN, MR, and MHC class II (HLA-
DR) as assessed by flow cytometry.
CD4
 

 
 T cells were separated from PBMCs using the CD4
 

 
 T
Cell Isolation kit according to the manufacturer’s protocol (Mil-
tenyi Biotec). Alternatively, PBMCs (which were first depleted of
the CD14
 

 
 cells used to generate iMDDCs) were kept in culture,
and on the day of the experiment, the CD4
 

 
 T cell population
was obtained by adding anti–HLA-DR, -CD8, and -CD11b
MACS beads to the CD14-depleted PBMC suspension. The pu-
rity of CD4
 

 
 T cells was 
 

 
95% as confirmed by flow cytometry.
 
Visualization of HIV-1 Captured by iMDDCs or CD4
 

 
 T
Cells.
 
5 
 

 
 10
 
5
 
 iMDDCs or CD4
 

 
 T cells were placed into 1.5-
ml Eppendorf tubes and resuspended in 45 
 

 
l RPMI containing
10% FCS before the inhibitors (5 
 

 
l of each per tube) and/or
PBS (5 
 

 
l per tube) were added to the cells. TAK-779 (1 
 

 
M)
was added to each tube (except for the controls) combined with a
second drug as listed in the following: PBS, anti-CD4 RPA-T4
(20 
 

 
g/ml), mannan (200 
 

 
g/ml), DC-SIGN mAb (1:1 mixture
of clone 507 and 526; 20 
 

 
g/ml), mAb b12 (20 
 

 
g/ml), and
CD4-IgG2 (20 
 

 
g/ml). Two tubes of iMDDCs and CD4
 

 
 T
cells were incubated with PBS only. After 1 h at 37
 

 
C, drug pre-
treated cells were exposed to AT-2 HIV-1
 
ADA
 
 (300 
 

 
g p24/1
 

 
10
 
5
 
 cells in 50 
 

 
l per tube) except for one tube of each cell type,
which served as negative control and received the equivalent
amount of buffer (1% BSA in PBS). After a further 2-h incuba-
tion at 37
 

 
C, cells were placed onto ice and washed using a re-
frigerated microfuge (3,000 rpm for 3 min). This was repeated
four times, each time resuspending the cells in 1 ml of cold se-
rum-free RPMI to remove cell-free virus and/or drugs before vi-
able cells were recounted by trypan blue exclusion and moni-
tored for the presence of viral protein by immunostaining (15).
Immunofluorescent staining was applied in order to assert the
potency of several inhibitors (directed either against the envelope
protein gp120 or cell surface markers) to block virus uptake. To
identify iMDDCs or CD4
 

 
 T cell–associated virus, either the
biotinylated tetravalent human CD4-IgG2 recognizing the CD4-
binding epitope of conformationally intact gp120 (16) or a mouse
mAb (clone 183-H12–5C) that reacts with HIV-1 p24 gag pro-
tein was used. For signal amplification of labeled cells, the TSA™
kit carrying the fluorochrome FITC was used. The immuno-
staining for viral envelope (Env) glycoprotein and gag protein
was performed as previously described except that an anti-p24 Ab
was used instead of an anti-p27 Ab (15).
 
HIV-1 Capture and Transfer Assay.
 
HIV-1 capture and trans-
fer assay was performed as described previously with minor mod-
ifications (17, 18). iMDDCs or DC-SIGN–expressing THP1
cells were seeded in triplicates into wells of round-bottom 96-
well plates (2 
 

 
 10
 
5
 
 cells/well). Cells were preincubated in the
presence or absence of inhibitors for 1 h at 37
 

 
C before exposure
to HIV-1 for 2 h at 37
 

 
C. Cells were extensively washed to
remove unbound virus and inhibitors and lysed in 1% Triton
X-100. Virus capture was measured by p24 ELISA. For the virus
transfer assay, cells pretreated with inhibitors and pulsed with vi-
rus were extensively washed and removed to fresh plates to co-
culture with PM1 cells (0.5 
 

 
 10
 
5
 
 cells/well) at 37
 

 
C. The super-
natants were collected every 3–4 d and stored at 
 

 
80
 

 
C until
virus replication was monitored by p24 ELISA.
 
p24 ELISA and Multiplex Quantitative PCR.
 
p24 antigen was
measured by ELISA at day 14 for explants and day 7 for cells (un-
less indicated) according to the manufacturer’s protocol (Beck-
man Coulter). Where indicated, multiplex quantitative PCR for
HIV-1 DNA and 
 

 
-actin was performed on extracted DNA as
described previously (3).
 
gp120 Binding Assay.
 
The gp120 binding assay was performed
as described previously with minor modifications (19). In brief,
HeLa cells were infected for 1 h at 37
 

 
C with the vTF7–3 vac-
cinia virus and transfected for 5 h with the BaL gp120/pcDNA3
construct using Lipofectamine 2000 (Invitrogen). After a 16-h in-
cubation at 37
 

 
C, cultures were metabolically labeled for 20 h
at 37
 

 
C in Met-free/Cys-free DMEM (Sigma-Aldrich) supple-
mented with 100 
 

 
Ci/ml of 
 
35
 
S Met/Cys (ICN Biomedicals). La-
beled cell supernatants were harvested and stored at 4
 

 
C until used
for binding. iMDDCs (5 
 

 
 10
 
6
 
) were incubated in the presence
or absence of inhibitors for 1 h at room temperature. Then, cells
were resuspended in 500 
 

 
l of supernatant containing 
 
35
 
S-labeled
gp120 and rocked gently for 2 h at room temperature. Cells were
pelleted, washed with PBS, and lysed in 0.5% NP-40 for 4 h at
4
 

 
C. Lysates of cells were clarified by centrifugation and subse-
quently incubated with HIVIG and protein G–Sepharose (Sigma-
Aldrich) rotating overnight at 4
 

 
C. Immune complexes bound by
the protein G–Sepharose were extensively washed, resuspended in
SDS loading buffer, and resolved by 7.5% SDS-PAGE (Bio-Rad
Laboratories). Autoradiographed gels were analyzed and quanti-
tated using the PhosphorImager (Molecular Dynamics Storm 840;
Amersham Bioscience).
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Results
 
HIV-1 Infection of Unstimulated Cervical Explants Is Inhibited
by Either CD4 mAb or CCR5 Inhibitor.
 
We have demon-
strated previously preferential replication of the R5 virus
HIV-1
 
BaL
 
 in cervical tissues that were not exogenously stim-
ulated or activated. To identify the predominant receptors
mediating infection of cervical tissue, we used inhibitors of
HIV-1
 
BaL
 
 attachment or entry. Cervical explants were incu-
bated with or without inhibitors specific for CD4 and CCR5
for 1 h before virus addition for 2 h. After incubation, the
cervical explants were then extensively washed to remove
unbound virus and inhibitors and cultured for 14 d. Both the
anti-CD4 mAb RPA-T4 (20 
 

 
g/ml) (9) and the CCR5 in-
hibitor TAK-779 (1 
 

 
M) (20) efficiently (
 

 
90%) inhibited
HIV-1
 
BaL
 
 infection (Fig. 1 A). There was no additional inhibi-
tion when mannan (200 
 

 
g/ml) was added to block any po-
tential interactions of HIV-1
 
BaL
 
 with MCLRs. Hence, block-
ade of either CD4 or CCR5 is sufficient to inhibit HIV-1
 
BaL
 
infection of nonstimulated human cervical tissue ex vivo.
CCR5 and CXCR4 Are Predominant HIV-1 Coreceptors
in Activated Cervical Tissue. To determine the coreceptors
used by HIV-1 in activated tissue (PHA stimulated), we
used coreceptor inhibitors and R5-, X4-, or R5X4-tropic
isolates (Fig. 1 B). AOP-RANTES (inhibitor targeted at
CCR5 and CCR3; 100 nM) (21), and TAK-779 (CCR5
inhibitor with a limited effect on CCR2b; 1 M) (20) in-
hibited infection by two different R5 isolates (SL2 and
BaL). Since neither isolate can utilize CCR2b, CCR5 is
considered to be their principal coreceptor in activated cer-
vical tissue. As expected, the CXCR4 inhibitor AMD3100
(1 M) (22) inhibited X4 viruses NL4–3 and 2044 only.
Cell entry of the primary virus isolate 2076, which can uti-
lize CCR5, CXCR4, CCR3, CCR8, and CXCR6 in
coreceptor-transfected cells in vitro (23), was only inhib-
ited when activated cervical tissue was pretreated with both
AMD3100 and TAK-779, but inhibition was complete
when both inhibitors were present. Hence, coreceptors
other than CCR5 or CXCR4 appear unimportant for in-
fection, but protection against dual-tropic viruses is likely
to require blockade of both coreceptors, CCR5 and
CXCR4. Mannan (200 g/ml) had no effect on HIV-1
infection of activated cervical tissue.
Migratory Cells Emigrating from Cervical Tissue Efficiently
Capture and Transmit HIV-1 Infection In Trans. Although the
above studies show that blockade of CD4 alone or of
CCR5 and/or CXCR4 can efficiently inhibit HIV-1 in-
fection of cells within cervical tissue, they do not address
whether whole HIV-1 can be taken up by migratory cells
in the absence of infection. Here, the role of MCLR DCs
Figure 1. Receptor blockade inhibits HIV-1 infection of cervical explant
tissue. (A) Unstimulated or (B) PHA-activated cervical explants were
incubated with inhibitors for 1 h at 37C before exposure to (A) HIV-1BaL or
(B) NL4–3, 2044, 2076, SL2, and BaL for 2 h at 37C. After incubation,
explants were extensively washed and cultured at 37C for 14 d. Virus
production in the absence of inhibitor was defined as 100% and was (A)
1.92 ng/ml or (B) 1.39 (NL4.3, open bar), 1.04 (2044, hatched bar), 0.94
(2076, black bar), 0.79 (SL2, vertical hatched bar), and 1.70 ng/ml (BaL,
gray bar). The data shown are representative of four independent experiments
from separate donors yielding similar results, with each p24 determination
shown as the mean (	 SD) of triplicate determinations. Proviral DNA
accumulation (A) at day 14 was determined by quantitative real-time
PCR using LTR primers. -Actin primers were used to control for total
amount of DNA.
Figure 2. Inhibition of localized mucosal HIV-1 infection and dissemi-
nation pathways. Human cervical explants were incubated with inhibitors
for 1 h at 37C before exposure to HIV-1BaL for 2 h at 37C. After incu-
bation, explants were extensively washed and cultured in the presence of
100 ng/ml of MIP-3 for 48 h. Emigrated wells were collected, washed,
and cocultured with PM1 cells. The explants were cultured in separate
wells. The data shown represent mean p24 antigen release (	 SD) from
both (A) cultured explants and (B) cocultured migratory cells and were
derived from three separate donors with each determination performed in
triplicates. Virus production in the absence of inhibitor was defined as
100% and was 0.99 and 1.26 ng/ml for the cervical explants and migratory
cells, respectively.
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may be particularly important (8, 10, 11, 24). To examine
this pathway, we collected migratory cells emigrating from
cervical explants 48 h after HIV-1 inoculation in the pres-
ence or absence of inhibitors and then cocultured them
with indicator cells (PM1) to determine whether they con-
tained infectious virus. Additionally, after removal of the
migratory cells the remaining explants were cultured for
another 14 d before measurement of HIV-1 replication. As
found previously in cervical tissue, the CD4 mAb RPA-T4
alone (20 g/ml) or TAK-779 and AMD3100 together (1
M) completely blocked HIV-1 infection with either R5
HIV-1BaL (Fig. 2 A) or HIV-1BaL in combination with X4
HIV-1NL4.3 (not depicted), whereas mannan (200 g/ml)
had no effect. In marked contrast, the combination of
TAK-779 with AMD3100 almost completely failed to in-
hibit the uptake of infectious HIV-1 by migratory cells,
whereas the CD4 mAb RPA-T4 and mannan were each
partially inhibitory (45 and 40%, respectively) (Fig. 2
B). Substantial inhibition (80%) of the uptake of infec-
tious HIV-1 by migratory cells was only achieved when
RPA-T4 was combined with mannan. Hence, these data
suggest that migratory cells can capture infectious HIV-1
by processes involving both CD4 and MCLRs even in the
presence of coreceptor inhibitors.
Multiple Receptors Are Involved in HIV-1 Uptake by Migra-
tory Cells. Since mannan is not specific for any individual
MCLR, we next used blocking Abs against DC-SIGN (18),
MR (25), and the mannose-independent HIV-1 ligand,
GalCer (26). Consistent with the lack of inhibition we saw
using mannan, mAbs to DC-SIGN, MR, and GalCer (each
at 20 g/ml) neither affected HIV-1 infection of cervical
tissue nor enhanced the protective effect of the anti-CD4
mAb RPA-T4 (20 g/ml) (Fig. 3 A and not depicted).
However, when migrated cells from these explants were
collected and cocultured with PM1 cells the DC-SIGN
mAb modestly but detectably (30%) inhibited HIV-1 up-
take and significantly (70%) inhibited uptake when com-
bined with RPA-T4 (Fig. 3 B), albeit to a lesser extent than
mannan (Fig. 2 B). The mAbs against MR (partial inhibitor
of gp120 binding to MR-expressing transfectants [25]) and
GalCer did not inhibit HIV-1 uptake (not depicted) and
when combined with RPA-T4 did not increase its inhibi-
tion provided by RPA-T4 alone (Fig. 3 B). No inhibition
was observed when control mouse IgG (20 g/ml) was
used. These experiments suggest that although DC-SIGN
does not play a major role in potentiating localized mucosal
infection by HIV-1 within cervical tissue, it is involved in
the uptake of virus by migratory cells.
HIV-1 Neutralizing mAb b12 and the CD4-IgG2 Protein
Inhibit Both Localized Mucosal Infection and Dissemination
Pathways. We also studied the effect of directly targeting
HIV-1 gp120 rather than its cognate receptors using the
broadly neutralizing human mAb b12 (27) and CD4-IgG2
(or PRO542), a tetrameric fusion protein between CD4
and IgG to block the CD4 interactions of gp120 (16). Sim-
ilar to what was observed using RPA-T4, b12 (20 g/ml)
and CD4-IgG2 (20 g/ml) potently inhibited HIV-1 in-
fection of cervical tissue (Fig. 4 A), but in contrast to RPA-
T4 and coreceptor inhibitors, b12 (20 g/ml) and CD4-
IgG2 (20 g/ml) also inhibited transfer of infectious virus
from migratory cells to susceptible indicator cells (Fig. 4 B).
No inhibition was observed when control human IgG (20
g/ml) was used. It is possible that enough Env-bound b12
or CD4-IgG2 remains associated with the virus taken up
by migratory cells for the virus to remain neutralized.
However, insufficient coreceptor inhibitor remains associ-
ated with cells for fusion to be blocked when virus is later
transferred to susceptible cells.
Characterization of Migratory Cells from Cervical Explants.
To characterize cells migrating from cervical tissues, cervi-
cal explants were cultured for 12–48 h to collect emigrant
cells. The majority of DCs emigrated out quickly during
Figure 3. Multiple receptors are involved in HIV-1 uptake by migra-
tory cells. Experiments were performed as described in the legend for
Fig. 2. The data shown represent mean p24 antigen release (	 SD) from
both (A) cultured explants and (B) cocultured migratory cells and were
derived from two separate donors with each determination performed in
triplicates. Virus production in the absence of inhibitor was defined as
100% and was 1.62 and 2.11 ng/ml for the cervical explants and migratory
cells, respectively.
Figure 4. mAb b12 and CD4-
IgG2 inhibit localized mucosal
infection and dissemination
pathways. Experiments were
performed as described in the
legend for Fig. 2. The data
shown represent mean p24 antigen
release (	 SD) from both (A)
cultured explants and (B) cocul-
tured migratory cells and were
derived from two separate donors
with each determination per-
formed in triplicates. Virus pro-
duction in the absence of inhibitor
was defined as 100% and was
1.73 and 1.88 ng/ml for the
cervical explants and migratory
cells, respectively.
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the first 24 h; the number of smaller lymphocytes emigrat-
ing out of tissue increased with time. Migratory cells were
stained with specific mAbs for FACS® or prepared on
slides for immunostaining. As shown in Fig. 5 A, two
major populations, CD3HLA-DR (R1: 45.26%) and
CD3HLA-DR (R2: 21.64%), were identified within
the migratory cells. A population of CD3HLA-DR
DC-T cell conjugates (28) was also apparent. Expression
of additional markers on the surface of CD3HLA-DR
and CD3HLA-DR was assessed using three-color
flow cytometry. CD4 cells were mainly found in the
CD3HLA-DR population, although the expression was
low. DC-SIGN cells were only identified among CD3HLA-
DR cells. However, some of the CD3HLA-DR cells
were negative for DC-SIGN, possibly due to the down-
regulation of DC-SIGN expression after DC emigration
or to the presence of an existing DC-SIGN DC popula-
tion (e.g., Langerhans cells).
Migratory DCs were large and irregular in shape and ex-
pressed high level of HLA-DR, MR, DC-SIGN, and the
mature DC marker CD83 (Fig. 5 B). CD3 lymphocytes
were round and much smaller than DCs. Although DCs
were consistently present in migratory cells, the number of
DC-SIGN cells was highly variable, suggesting down-
regulation after emigration or interdonor variability. The
morphological and phenotypic features of cervical DCs
were similar to those emigrated from macaque cervical ex-
plants as demonstrated previously (29). Within all prepa-
Figure 5. Characterization of cells emigrated from cervical
tissue. (A) Three-color FACS® analyses showed a typical
scatterplot distinguishing between large cells with high
granularity (CD3HLA-DR) and small cells with low
granularity (CD3HLA-DR). CD3HLA-DR and
CD3HLA-DR populations were gated to analyze their
CD4 and DC-SIGN expression. (B) Emigrated cells were
adhered to alcian blue–pretreated microscope slides and
stained with the indicated mAbs followed by incubation
with GAM Alexa Fluor594. Cell nuclei were stained using
DAPI. (C) Emigrated cells from HIV-1BaL–infected cervical
explants were separated using CD3 or HLA-DR Micro-
Beads. Negative and positive populations were cocultured
with PM1 cells. The data shown are representative of two
independent experiments derived from two separate donors.
Virus production in the coculture with nondepletion pop-
ulation was defined as 100% and was 8.9 ng/ml.
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rations, only a few langerin-positive cells were detected
(
1%; not depicted).
Subsequent experiments were performed to determine
relative contributions of CD3HLA-DR and CD3HLA-
DR populations to HIV-1 dissemination. Cervical ex-
plants were exposed to HIV-1BaL in the presence of 1 M
TAK-779 to block productive infection. After 2 h, un-
bound HIV-1 and TAK-779 were removed by extensive
washes, and explants were cultured for 48 h. Migratory
cells were collected and separated using CD3 or HLA-
DR MicroBeads, respectively; CD3 or HLA-DR and
CD3 or HLA-DR populations were then cocultured
with PM1 cells, and p24 antigen production was assessed
on day 7. As shown in Fig. 5 C, HLA-DR cells ac-
counted for as much as 90% of HIV-1 dissemination,
whereas CD3 cells contributed for only 30%. Together,
these results suggest that HIV-1 dissemination by migratory
cells is largely mediated by a CD3HLA-DR cell subset.
However, DC-T cell conjugates will also be represented in
the single positive fractions and may contribute to the
overall signal. This might be especially true for the CD3
population.
Visualizing HIV-1 Associated with CD4 T Cells and
iMDDCs. To determine efficiency and specificity of HIV-1
capture by the two migratory cell populations (HLA-DR,
CD3; see Fig. 5 C) in more detail, further investigations
were performed using purified CD4 T cells and iMDDCs
pulsed with AT-2–inactivated HIV-1ADA (R5), and virus
was detected by p24 antigen and Env staining. AT-2 virus
capture by DCs has been shown to reflect the capture of
live virus (15), providing a safe and reliable measure of
DC-virus interplay. As shown in Fig. 6 A, in the absence
of TAK-779 HIV-1 captured by iMDDCs was far more ef-
ficient than that observed for CD4 T cells as assessed by
both anti-p24 mAb and biotinylated CD4-IgG2 (Env
gp120) stains. In the presence of 1 M TAK-779 (Fig. 6
B), no significant reduction of bound HIV-1 was observed
in iMDDCs and CD4 T cells (compared with PBS con-
trol), indicating that TAK-779 does not block HIV-1 up-
take. But the amount of cell-associated virus captured by
CD4 T cells was decreased in the presence of CD4-IgG2
(20 g/ml), CD4 mAb RPA-T4 (20 g/ml), and b12 (20
g/ml) but not in the presence of DC-SIGN mAb (20 g/
ml) or mannan (200 g/ml) in CD4 T cells (Fig. 6 B). In
contrast, for iMDDCs no significant reduction in HIV-1
uptake was detected in the presence of any of the inhibitors
(CD4-IgG2, CD4 mAb, b12, DC-SIGN mAb, and man-
nan) in combination with TAK-779 (Fig. 6 B).
mAb b12 and CD4-IgG2 Render Bound Virus Noninfec-
tious. To test the hypothesis that enough Env-bound b12
or CD4-IgG2 remains associated with the virus taken up
by migratory cells for the virus to be neutralized, iMDDCs
and DC-SIGN–expressing THP1 cells were used to study
HIV-1 capture and transfer. As shown in Fig. 7 A, b12 (20
g/ml) showed only a marginal effect, and CD4-IgG2 (20
g/ml) had no effect on HIV-1BaL capture by iMDDCs
and DC-SIGN–expressing THP1 cells. Although DC-
SIGN mAb (20 g/ml) and mannan (200 g/ml) partially
blocked HIV-1 uptake by iMDDCs (55% by mannan
and 45% by DC-SIGN mAb), they completely blocked
HIV-1 capture by DC-SIGN–expressing THP1 cells, sup-
porting the involvement of attachment receptors other
than MCLRs for HIV-1 capture by iMDDCs. Similar ob-
servations were made in the HIV-1 capture and transfer
experiment (Fig. 7 B). DC-SIGN mAb and mannan
completely blocked HIV-1BaL transfer from DC-SIGN–
expressing THP1 cells to target cells (95%) but only par-
tially blocked transfer of HIV-1 BaL from iMDDCs to
indicator cells (35 and 45%, respectively), again sug-
gesting the involvement of other receptors in HIV-1 cap-
ture than those blocked by DC-SIGN mAb or mannan.
Of interest, b12 and CD4-IgG2, which had no effect on
HIV-1 association with iMDDCs and DC-SIGN–express-
ing THP1 cells, completely inhibited the transmission of in-
fectious virus from iMDDCs and DC-SIGN–expressing
THP1 cells to target cells (95%). Thus, although virus
Figure 6. Visualizing HIV-1 captured by CD4 T cells or iMDDCs. iMDDCs or CD4 T cells were incubated for 1 h at 37C with (A) PBS or (B)
TAK-779 combined with a second inhibitor as listed. After exposure to AT-2 HIV-1ADA for 2 h at 37C, cells were washed, adhered to alcian blue–
pretreated slides, and monitored for the presence of (A) Env versus p24 gag protein using the biotinylated CD4-IgG2 and HRP-conjugated streptavidin
versus an anti-p24 mAb combined with a HRP-conjugated GAM Ab or (B) Env using the biotinylated CD4-IgG2 and HRP-conjugated steptavidin. Signal
amplification was achieved by using the TSA kit. Nuclei were stained with DAPI. Representative results out of three independent experiments are shown.
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neutralized by either b12 or CD4-IgG2 still binds to iMD-
DCs/DC-SIGN–expressing THP1 cells, such neutralized
virus does not infect T cells in trans.
MCLRs and CD4 Are the Principal Receptors for gp120, But
Other Mechanisms May Account for Virus Capture and Transfer.
Based on the observation that CD4 mAb in combination
with either DC-SIGN mAb (20 g/ml) or mannan (200
g/ml) only partially inhibited HIV-1 uptake by iMDDCs
and transfer to target cells (60–70%; Fig. 7 C), we exam-
ined whether there are additional receptors involved for
HIV-1 binding to iMDDCs. To do so, gp120 binding to
iMDDCs in the presence or absence of specific inhibitors
was performed. As shown in Fig. 7 D, mannan (200 g/
ml) and DC-SIGN mAb (20 g/ml) alone inhibited BaL
gp120 binding to iMDDCs (80 and 55%, respectively).
CD4 mAb (20 g/ml) by itself had a marginal inhibitory
effect on BaL gp120 binding to iMDDCs (10%). In con-
trast, the combination of CD4 mAb with mannan (95%)
or DC-SIGN mAb (85%) almost completely blocked
BaL gp120 binding to iMDDCs. Together these data sug-
gest that BaL gp120 binding to iMDDCs mainly involves
MCLRs and CD4. The inefficient blockade of virus trans-
fer by CD4 mAb and mannan in combination (Fig. 7 C)
suggests that other mechanisms may account for virus
transfer by iMDDCs.
Discussion
In vivo studies from the SIV-infected macaque model
and human epidemiologic evidence together suggest that
during sexual transmission HIV-1 enters the mucosa of the
cervix and vagina (2). To enter coreceptor-transfected cells,
HIV-1 has been reported to utilize more than a dozen
seven-transmembrane receptors (30), including CCR5,
CCR3, CCR2b, and CXCR4, which are expressed in the
human cervix and vaginal mucosa (6, 31, 32). By conduct-
ing coreceptor-targeted blocking experiments, our results
indicate that the only relevant coreceptors for HIV-1 in
cervix are CCR5 and CXCR4, suggesting that CCR5 and
CXCR4 are the predominant coreceptors for HIV-1 infec-
tion of cervix in vivo. These results are consistent with
what was found in studies of primary human and macaque
lymphocytes (33). The R5X4 isolate 2076, which uses
both CCR5 and CXCR4 (23), was not inhibited by either
the CCR5 inhibitor TAK-779 or the CXCR4 inhibitor
AMD3100, whereas inhibition was complete when both
inhibitors were present. Thus, R5X4 isolates may enter the
cervix via both coreceptors, CCR5 and CXCR4. Given
the broad repertoire of viral isolates present in infectious se-
men (5), these findings provide information that both
CCR5 and CXCR4 should be considered when develop-
ing topical microbicides.
The distribution of DCs in vagina and ectocervix
may allow them to be one of the first cell types to contact
HIV-1. DCs express CD4, DC-SIGN, and MCLRs that
may facilitate capture of HIV-1. It has been documented
that different subsets of DCs express unique members of
the MCLR family. For instance, DCs in vaginal epithelium
express langerin (CD207) but not DC-SIGN and MR,
whereas DCs in the lamina propria express DC-SIGN and
MR but not langerin (9, 24). By using an ex vivo cervical
explant model in which the cells represent the resident im-
mune population in terms of their phenotype and anatomi-
cal location, we demonstrate that blockade of the primary
receptors for HIV-1 infection, CD4 or CCR5 or/and
CXCR4, is sufficient to inhibit localized HIV-1 infection
of human cervical tissue. Interestingly, GalCer or MR ap-
peared to play no part in localized infection of cervical tis-
sue and dissemination of virus to target cells in our system
(25, 26, 34). In the present study, MR was found to be ex-
Figure 7. mAb b12 and CD4-
IgG2 render bound virus nonin-
fectious. iMDDCs and DC-
SIGN-expressing THP1 cells were
incubated with indicated inhibitors
for 1 h at 37C before exposure
to HIV-1BaL for 2 h at 37C.
Cells were extensively washed
and either lysed for capture assay
(A) or cocultured with PM1
cells (B and C) for transfer assay.
(A) Virus captured by iMDDCs
or THP1-DC-SIGN in the ab-
sence of inhibitors was defined
as 100% and was 1.76 ng/ml
(THP1-DC-SIGN) and 1.58 ng/
ml (iMDDCs). (B) Virus transfer
from iMDDCs or THP1–DC-
SIGN cells to PM1 cells in the
absence of inhibitors was defined
as 100% and was 65.8 ng/ml
(THP1–DC-SIGN) and 59.4 ng/ml (iMDDCs). (C) Virus transfer from iMDDCs to PM1 cells in the absence of inhibitors was defined as 100% and was
83.6 ng/ml. The data shown are representative of at least two independent experiments yielding similar results with each p24 shown as the mean (	 SD)
of triplicate determinations. (D) Radiolabeled BaL gp120 binds to iMDDCs in the presence or absence of inhibitors. Autoradiographed gels were
analyzed and quantitated using the PhosphorImager. One representative experiment out of three is shown. The value (band intensity) in the absence of
inhibitors was arbitrarily set to 100%.
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pressed on DC subset of cells emigrated from cervical tis-
sues. MR mAb (clone19.2; BD Biosciences) was unable to
block HIV-1 take-up by migratory cells, suggesting that
HIV-1 could bind to CD4, other MCLRs, and/or other
MR (not recognized by the mAb). However, it is possible
that the partial blocking activities of the MR (and other)
mAb (25) may have contributed to the incomplete inhibi-
tion we observed. Indeed, further studies indicate that inhi-
bition of HIV-1 uptake and subsequent transmission to T
lymphocytes by migratory cells required blockade of both
CD4 and MCLRs. The observation that mannan had no
effect on HIV-1 infection within tissues across a range of
viral titers (5  103–5  105 TCID50) suggests that
MCLRs may have little impact on localized infection
within cervical tissue. In contrast, MCLR-dependent up-
take and dissemination of virus by migratory cells occurs
even in tissue explants that remain p24 negative after in
vitro exposure to HIV-1 (unpublished data). This suggests
that dissemination of virus by migratory cells may be more
efficient than establishment of localized infection.
Although DC-SIGN seems to be responsible for a con-
siderable fraction of HIV-1 uptake by MCLRs on cervical
cells, additional receptors are also likely to contribute as has
been reported for other DC subsets (24). Flow cytometric
analyses of cells emigrating from tissue explants reveal two
major populations, CD3HLA-DR and CD3HLA-
DR. Further experiments demonstrated that migratory
DCs were large and irregular in shape and express high
level of HLA-DR; these DCs also express MR, DC-SIGN,
and the mature DCs marker CD83. The number of lan-
gerin-positive cells was very low (
1%). Although DCs
were consistently observed within migratory population,
the number of DC-SIGN cells appeared more variable
(5–25% from donor to donor, n  7; unpublished data).
The relatively low expression of DC-SIGN on migratory
cells may be due to its down-regulation after DC migration
as suggested by findings in skin and tonsil models (24). It is
not clear if there is interindividual heterogeneity regarding
DC-SIGN expression. Recent studies indicate that inflam-
matory diseases and acute HIV-1 infection may increase
DC-SIGN–positive DC populations (35, 36), implicating
the possibility of DC-SIGN heterogeneity. More individu-
als need to be investigated to address this issue.
Although simultaneous blockade of CD4 and DC-SIGN
did not completely suppress HIV-1 transmission from mi-
gratory cells to T cells, direct targeting of HIV-1 by the
neutralizing mAb b12 and sCD4 fusion protein CD4-IgG2
was sufficient to inhibit both localized infection and dis-
semination pathways. Using iMDDCs and DC-SIGN–
expressing THP1 cells, it has been demonstrated that virus
neutralized by either b12 or CD4-IgG2 still binds to iMD-
DCs and DC-SIGN, but the bound virus remains nonin-
fectious. These in vitro observations are supported by the
demonstration that vaginal application of b12 but not the
CCR5 inhibitor CMPD167 can prevent SHIV-162P4
transmission to macaques (37, 38). Of interest, HIV-1 up-
take appears more complex in iMDDCs as blockade of
both CD4 and MCLRs was unable to completely inhibit
HIV-1 uptake by iMDDCs and subsequent transfer to T
cells, whereas gp120 binding assays indicate that MCLRs
and CD4 are the main receptors for gp120 on iMDDCs.
Our findings suggest the existence of additional pathways
for HIV-1 virus capture/transfer by iMDDCs. Although it
is accepted that MDDCs can capture HIV via DC-SIGN,
conflicting data have been reported regarding the propor-
tional contribution of DC-SIGN to HIV-1 uptake by
MDDCs (9, 13, 14, 17, 18, 39–41). This inconsistency may
be attributed to difference in viral strain, inhibitor used,
MDDCs preparation, and methodology.
These findings have particular significance for the design
of potential topical microbicides for the prevention of
HIV-1 infection of women (1, 42). Topically applied com-
pounds will form a diffusion gradient across mucosal tissue
dependent on their permeability characteristics. Agents tar-
geted against HIV-1 itself, such as b12 mAb and CD4-
IgG2, will be active within the vaginal or cervical mucosa
but will need to be maintained at sufficiently high levels to
neutralize incoming virus before uptake and dissemination
by migratory cells (37). In contrast to b12 mAb and CD4-
IgG2, many fusion and attachment inhibitors, including
coreceptor inhibitors, need to reach target cells within gen-
ital mucosa before or concomitant with viral exposure (38).
However, uptake of HIV-1 by migratory cells may trans-
port virus away from localized inhibitory concentrations of
topically applied agents rendering them ineffective.
These observations suggest that strategies aimed at block-
ade of HIV-1 uptake by cells within genital mucosa should
target both localized infection and dissemination pathways
and provide a frame of reference for future in vitro evalua-
tion of microbicide candidates. Our identification of the
predominant receptors involved in HIV-1 infection and
dissemination within human cervical tissue suggests that
targeted blockade of attachment and fusion receptors may
protect against HIV-1 transmission. These findings may
provide important direction for the successful development
of effective HIV-1 prevention strategies.
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